- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07431112
En fase 1-studie af AIR-001 hos voksne med alfa-1-antitrypsinmangel (AATD) (RepAIR1)
Fase 1, åben-label, enkelt stigende dosis og multipledosisundersøgelse til vurdering af sikkerhed, tolerabilitet, farmakokinetik og farmakodynamik ved subkutant administration af AIR-001 hos voksne med AATD på grund af PiZZ-genotypen
This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.
Studieoversigt
Status
Betingelser
Intervention / Behandling
- Medicin: AIR-001 SAD dose level 1
- Medicin: AIR-001 SAD dose level 2
- Medicin: AIR-001 SAD dose level 3
- Medicin: AIR-001 SAD dose level 4
- Medicin: AIR-001 MD dose level 1
- Medicin: AIR-001 MD dose level 2
- Medicin: AIR-001 MD dose level 3
- Medicin: AIR-001 MD dose level 4
- Medicin: AIR-001 MD dose level 5
- Medicin: AIR-001 MD dose level 6
Detaljeret beskrivelse
The study is designed to evaluate the safety, tolerability, PK, and PD of AIR-001.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: AIRNA Corporation Clinical Trials Information
- Telefonnummer: 617-609-8790
- E-mail: patients@airna.com
Studiesteder
-
-
-
Melbourne, Australien
- Rekruttering
- Clinical Study Center
-
-
-
-
-
Cambridge, Det Forenede Kongerige
- Rekruttering
- Clinical Study Center
-
London, Det Forenede Kongerige
- Rekruttering
- Clinical Study Center
-
Southampton, Det Forenede Kongerige
- Rekruttering
- Clinical Study Center
-
-
-
-
-
Tbilisi, Georgien
- Trukket tilbage
- Clinical Study Center 1
-
Tbilisi, Georgien
- Afsluttet
- Clinical Study Center 2
-
-
-
-
-
Leiden, Holland
- Rekruttering
- Clinical Study Center
-
-
-
-
-
Auckland, New Zealand
- Rekruttering
- Clinical Study Center
-
-
-
-
-
Matosinhos Municipality, Portugal
- Rekruttering
- Clinical Study Center
-
-
-
-
-
Barcelona, Spanien
- Rekruttering
- Clinical Study Center
-
-
-
-
-
Stockholm, Sverige
- Rekruttering
- Clinical Study Center
-
-
-
-
-
Hanover, Tyskland
- Rekruttering
- Clinical Study Center
-
Tübingen, Tyskland
- Rekruttering
- Clinical Study Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female participants >18 years and <75 years of age at the time of signing informed consent
- Total serum AAT levels < 11µM (57 mg/dL)
- Pi*ZZ genotype confirmed by DNA sequencing within the SERPINA1 gene with no known co-occurring SERPINA1 null variants
- Spirometry: Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted
- Non-smoker, including vaping, for at least 6 months prior to screening
- Body mass index between 18-33.0 kg/m²
- Body weight ≥ 45 kg and ≤110 kg
- Willing and able to give written informed consent prior to the initiation of any study procedure by the participant
- Negative beta human chorionic gonadotropin (β-hCG) at enrolment for women of childbearing potential (WOCBP) only.
- Participants who are either a WOCBP or male participant who is heterosexually active with a WOCBP must consent to use a highly effective method of contraception from screening visit until at least 4 weeks after the last dose of investigational medicinal product (IMP).
- Willing and able to comply with the study design schedule, all study procedures, and other requirements
Exclusion Criteria:
-
Female participants who are nursing or lactating
-
Participant has received AAT augmentation therapy within 30 days prior to Screening Visit or plans to receive AAT augmentation therapy at any time during study participation.
-
Known or suspected allergy or intolerance to AIR-001 or its components
-
Acute respiratory tract infection or clinically-diagnosed chronic obstructive pulmonary disease (COPD) exacerbation that required antibiotic treatment and/or systemic corticosteroids within the 8 weeks prior to dosing.
-
Positive screening test for COVID-19 and/or Influenza.
-
Lung disease that requires use of continuous oral corticosteroids, continuous supplemental oxygen, day-time ventilatory support, or any participant who is on a lung transplant waiting list.
-
Liver Fibrosis score > 10 kPa defined by screening liver elastography, historical liver biopsy showing ≥ F3 fibrosis (METAVIR or comparable scoring system), or established diagnosis of hepatic cirrhosis.
-
Any of the following screening laboratory abnormalities:
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) > 3 x upper limit of normal (ULN)
- Total bilirubin > ULN (note: for participants with documented Gilbert's syndrome and direct bilirubin ≤ ULN , exclusion criterion is total bilirubin is > 2.5 mg/dL)
- INR > ULN (for participants taking stable doses of anticoagulants, the exclusion criterion is INR > 3.0)
- Platelet count ≤ 150 k/μL
- Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73m² by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation
- Urine Albumin-to-Creatinine Ratio > 300 mg/g
- Urine Protein-to-Creatinine Ratio > 500 mg/g
-
Prolonged QT interval on electrocardiogram (ECG), defined as QTcF ≥ 450ms (men) or ≥ 470ms (women)
-
ECG findings at screening that render measurements of QT interval imprecise.
-
History of congestive heart failure, serious cardiac arrythmias requiring anti-arrhythmic medications or unexplained black-outs or fainting episodes with a suspected cardiac origin
-
Positive screening test or known chronic infection with Hepatitis B, Hepatitis C, or HIV.
-
Known history of coagulopathy or bleeding diathesis
-
History or intolerance to subcutaneous (SC) injection including relevant dermatological conditions affecting standard injection sites
-
History or presence of any medical condition, behavioral or psychiatric disorder, or planned surgical procedure or surgical history that may interfere with participation in the study or interpretation of study results, and/or put the participant at significant risk (in the opinion of the investigator) if he/she participates in the study.
-
History of any lung-volume reduction procedure in the 6 months prior to screening.
-
Laboratory value(s) outside the laboratory reference range that is (are) considered to be clinically significant and may affect the safety, efficacy, PK, or PD assessments or interpretation by the Investigator, at screening
-
History of alcohol or drug abuse within the past three months
-
Current or previous participation in any other clinical study where the participant has received a dose of an IMP within 3 months or 5 half-lives of the IMP, whichever is longest, prior to Screening Visit
-
Any previous gene replacement or DNA-editing therapy
-
Any previous use of an RNA-based therapeutic (except for AIR-001 or RNA-based vaccines) within the 6 months prior to the Screening Visit or at any time if stopped due to drug-related adverse event.
-
Use of any new prescription, vaccine, herbal remedy, over-the-counter medication, or supplement, or changes in chronic therapies within the 28 days prior to dosing unless approved by study Medical Monitor.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: AIR-001 SAD Cohort 1
AIR-001 is an RNA-editing oligonucleotide in sterile preservative-free solution administered by subcutaneous (SC) injection as a single dose. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 SAD Cohort 2
AIR-001 administered by SC injection as a single dose. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 SAD Cohort 3
AIR-001 administered by SC injection as a single dose. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 SAD Cohort 4
AIR-001 administered by SC injection, single dose. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 MD Cohort 1
AIR-001 is an RNA-editing oligonucleotide in sterile preservative-free solution administered by subcutaneous (SC) injection as multiple doses. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 MD Cohort 2
AIR-001 administered by SC injection as multiple doses. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 MD Cohort 3
AIR-001 administered by SC injection as multiple doses. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 MD Cohort 4
AIR-001 administered by SC injection as multiple doses. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 MD Cohort 5
AIR-001 administered by SC injection as multiple doses. |
AIR-001 drug product, SC |
|
Eksperimentel: AIR-001 MD Cohort 6
AIR-001 administered by SC injection as multiple doses. |
AIR-001 drug product, SC |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal deltagere med behandlingsrelaterede bivirkninger (TEAE'er)
Tidsramme: Op til dag 169
|
Op til dag 169
|
|
Forekomst af laboratorieabnormiteter og ændringer fra baseline, herunder hematologi-, kemi-, koagulations- og urinanalyseparametre
Tidsramme: Baseline gennem op til dag 169
|
Baseline gennem op til dag 169
|
|
Forekomsten af abnormale vitale tegn
Tidsramme: Baseline gennem op til dag 169
|
Baseline gennem op til dag 169
|
|
Forekomst af abnormale elektrokardiogram (EKG) fund
Tidsramme: Baseline gennem op til dag 169
|
Baseline gennem op til dag 169
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Areal under plasma-koncentrationstidskurven for AIR-001 fra doseringstidspunktet til den sidste målbare koncentration (AUClast)
Tidsramme: Op til dag 169
|
Op til dag 169
|
|
Maksimal koncentration af AIR-001 i plasma (Cmax)
Tidsramme: Op til dag 169
|
Op til dag 169
|
|
Ændring fra baseline i niveauer af totalt serum AAT-protein, inklusive serum M-AAT, Z-AAT og funktionelt AAT-protein
Tidsramme: Op til dag 169
|
Op til dag 169
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Information, AIRNA Corporation
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Medfødte abnormiteter
- Lungesygdomme
- Genetiske sygdomme, medfødte
- Leversygdomme
- Luftvejssygdomme
- Patologiske processer
- Emfysem
- Spædbarn, Nyfødt, Sygdomme
- Alpha 1-antitrypsinmangel
- Patologiske tilstande, tegn og symptomer
- Subkutant emfysem
Andre undersøgelses-id-numre
- AIR-001-AATD-101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .